{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259073047", "close" : "1259096447", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
prnewswire

The Quigley Corporation to Announce Third Quarter Results and Host Audio Web Cast

  • Press Release
  • Source: The Quigley Corporation
  • On 7:00 am EST, Friday November 6, 2009

DOYLESTOWN, Pa., Nov. 6 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY - News), www.quigleyco.com, today announced it will issue its third quarter results at 8:30 AM (ET) on Thursday, November 12, 2009.

Related Quotes

SymbolPriceChange
QGLY2.29+0.14
Chart for The Quigley Corporation
{"s" : "qgly","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Ted Karkus, Chairman and CEO, will provide a Company overview, including a review of activities and third quarter results, on a conference call which will be web cast live on The Quigley Corporation's web site, (www.quigleyco.com), at 11:00 AM (ET) that morning.

A replay of the conference call will be available for 30 days on the Company web site.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY - News; http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma, Inc., (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:
    Ted Karkus                           Investor Relations
    Chairman of the Board, CEO           Carl Hymans
    The Quigley Corporation              G.S. Schwartz & Co.
    (215) 345-0919 ext. 114              212.725.4500 ext. 304
                                         carlh@schwartz.com

Sponsored Links

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.